top of page


AbbVie (2017). Marinol Prescribing Information (AbbVie Inc; North Chicago IL, 60064).

Abrams, D.I., Couey, P., Shade, S.B., Kelly, M.E., and Benowitz, N.L. (2011). Cannabinoid-opioid interaction in chronic pain. Clinical pharmacology and therapeutics 90, 844-851 Retrieved from

Abrams, D.I., Jay, C.A., Shade, S.B., Vizoso, H., Reda, H., Press, S., Kelly, M.E., Rowbotham, M.C., and Petersen, K.L. (2007). Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68, 515-521 Retrieved from

Aggarwal, S.K. (2016). Use of cannabinoids in cancer care: palliative care. Curr Oncol 23, S33-36.

Ahmed, A., van der Marck, M.A., van den Elsen, G., and Olde Rikkert, M. (2015). Cannabinoids in late-onset Alzheimer's disease. Clinical pharmacology and therapeutics 97, 597-606.

Ahmed, A., van der Marck, M.A., van den Elsen, G., and Olde Rikkert, M. (2015). Cannabinoids in late-onset Alzheimer's disease. Clinical pharmacology and therapeutics 97, 597-606 Retrieved from

Amtmann, D., Weydt, P., Johnson, K.L., Jensen, M.P., and Carter, G.T. (2004). Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care 21, 95-104.

Ashton, C.H. (2001). Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 178, 101-106 Retrieved from

Ballard, M.E., Bedi, G., and de Wit, H. (2012). Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images. Journal of psychopharmacology 26, 1289-1298 Retrieved from

Beal, J.E., Olson, R., Laubenstein, L., Morales, J.O., Bellman, P., Yangco, B., Lefkowitz, L., Plasse, T.F., and Shepard, K.V. (1995). Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10, 89-97 Retrieved from

Berman, J.S., Symonds, C., and Birch, R. (2004). Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 112, 299-306 Retrieved from


Blake, D.R., Robson, P., Ho, M., Jubb, R.W., and McCabe, C.S. (2006). Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45, 50-52 Retrieved from

Blazquez C, Chiarlone A, Sagredo O, Aguado T, Ruth Pazos M, Resel E, et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease. Brain : a journal of neurology. 2011;134:119-36.


Cameron, C., Watson, D., and Robinson, J. (2014). Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol 34, 559-564 Retrieved from

Cannabis In Cachexia Study, G., Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., Ko, Y.D., Schnelle, M., Reif, M., et al. (2006). Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24, 3394-3400 Retrieved from

Carter, G.T., Weydt, P., Kyashna-Tocha, M., and Abrams, D.I. (2004). Medicinal cannabis: rational guidelines for dosing. IDrugs 7, 464-470 Retrieved from

Carley, D.W., Prasad, B., Reid, K.J., Malkani, R., Attarian, H., Abbott, S.M., Vern, B., Xie, H., Yuan, C., and Zee, P.C. (2018). Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea. Sleep 41.

Chagas, M.H., Eckeli, A.L., Zuardi, A.W., Pena-Pereira, M.A., Sobreira-Neto, M.A., Sobreira, E.T., Camilo, M.R., Bergamaschi, M.M., Schenck, C.H., Hallak, J.E., et al. (2014). Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. Journal of clinical pharmacy and therapeutics 39, 564-566 Retrieved from

Clark, A.J., Ware, M.A., Yazer, E., Murray, T.J., and Lynch, M.E. (2004). Patterns of cannabis use among patients with multiple sclerosis. Neurology 62, 2098-2100 Retrieved from

Cone, E.J., Johnson, R.E., Paul, B.D., Mell, L.D., and Mitchell, J. (1988). Marijuana-laced brownies: behavioral effects, physiologic effects, and urinalysis in humans following ingestion. J Anal Toxicol 12, 169-175 Retrieved from

Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., and Schram, K. (1991). Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacology, biochemistry, and behavior 40, 701-708 Retrieved from

Consroe, P., Sandyk, R., and Snider, S.R. (1986). Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30, 277-282 Retrieved from

Cooper, R.E., Williams, E., Seegobin, S., Tye, C., Kuntsi, J., and Asherson, P. (2017). Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Eur Neuropsychopharmacol 27, 795-808.

Corey-Bloom, J., Wolfson, T., Gamst, A., Jin, S., Marcotte, T.D., Bentley, H., and Gouaux, B. (2012). Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 184, 1143-1150 Retrieved from

Crippa, J.A., Derenusson, G.N., Ferrari, T.B., Wichert-Ana, L., Duran, F.L., Martin-Santos, R., Simoes, M.V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of psychopharmacology 25, 121-130 Retrieved from

Curtis, A., Clarke, C.E., and Rickards, H.E. (2009a). Cannabinoids for Tourette's Syndrome. Cochrane Database Syst Rev, CD006565 Retrieved from

Curtis, A., Mitchell, I., Patel, S., Ives, N., and Rickards, H. (2009b). A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord 24, 2254-2259 Retrieved from

Curtis, A., and Rickards, H. (2006). Nabilone could treat chorea and irritability in Huntington's disease. The Journal of neuropsychiatry and clinical neurosciences 18, 553-554 Retrieved from

Das, R.K., Kamboj, S.K., Ramadas, M., Yogan, K., Gupta, V., Redman, E., Curran, H.V., and Morgan, C.J. (2013). Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology 226, 781-792 Retrieved from

Deiana, S., Watanabe, A., Yamasaki, Y., Amada, N., Arthur, M., Fleming, S., Woodcock, H., Dorward, P., Pigliacampo, B., Close, S., et al. (2012). Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Delta(9)-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology 219, 859-873 Retrieved from

Devinsky, O., Cross, J.H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I.E., Thiele, E.A., and Wright, S. (2017). Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine 376, 2011-2020 Retrieved from

Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., et al. (2016). Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 15, 270-278 Retrieved from

Duran, M., Perez, E., Abanades, S., Vidal, X., Saura, C., Majem, M., Arriola, E., Rabanal, M., Pastor, A., Farre, M., et al. (2010). Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. British journal of clinical pharmacology 70, 656-663 Retrieved from

Ellis, R.J., Toperoff, W., Vaida, F., van den Brande, G., Gonzales, J., Gouaux, B., Bentley, H., and Atkinson, J.H. (2009). Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 34, 672-680 Retrieved from

Esposito, G., De Filippis, D., Carnuccio, R., Izzo, A.A., and Iuvone, T. (2006). The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J Mol Med (Berl) 84, 253-258 Retrieved from

Eubanks, L.M., Rogers, C.J., Beuscher, A.E.t., Koob, G.F., Olson, A.J., Dickerson, T.J., and Janda, K.D. (2006). A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm 3, 773-777 Retrieved from

Flachenecker, P., Henze, T., and Zettl, U.K. (2014a). Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Eur Neurol 72, 95-102 Retrieved from

Flachenecker, P., Henze, T., and Zettl, U.K. (2014b). Nabiximols (THC/CBD oromucosal spray, Sativex(R)) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 71, 271-279 Retrieved from

Foroughi, M., Hendson, G., Sargent, M.A., and Steinbok, P. (2011). Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas--possible role of Cannabis inhalation. Childs Nerv Syst 27, 671-679.

Lewis, M.A., Russo, E.B, Smith, K.M. (2017) Pharmacological Foundations of Cannabis Chemovars

Journal: Planta Med 10.1055/s-0043-122240

Fox, S.H., Kellett, M., Moore, A.P., Crossman, A.R., and Brotchie, J.M. (2002). Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17, 145-149 Retrieved from 

Gibbs, M., Winsper, C., Marwaha, S., Gilbert, E., Broome, M., and Singh, S.P. (2015). Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord 171, 39-47.

Glass, R.M., Uhlenhuth, E.H., Hartel, F.W., Schuster, C.R., and Fischman, M.W. (1981). Single-dose study of nabilone in anxious volunteers. Journal of clinical pharmacology 21, 383S-396S Retrieved from

Gofshteyn, J.S., Wilfong, A., Devinsky, O., Bluvstein, J., Charuta, J., Ciliberto, M.A., Laux, L., and Marsh, E.D. (2017). Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases. J Child Neurol 32, 35-40 Retrieved from

Gomes, F.V., Casarotto, P.C., Resstel, L.B., and Guimaraes, F.S. (2011). Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice. Prog Neuropsychopharmacol Biol Psychiatry 35, 434-438.

Gong, H., Jr., Tashkin, D.P., Simmons, M.S., Calvarese, B., and Shapiro, B.J. (1984). Acute and subacute bronchial effects of oral cannabinoids. Clinical pharmacology and therapeutics 35, 26-32 Retrieved from

Grinspoon, L., and Bakalar, J.B. (1998). The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. J Psychoactive Drugs 30, 171-177 Retrieved from

Gruber, A.J., Pope, H.G., Jr., and Brown, M.E. (1996). Do patients use marijuana as an antidepressant? Depression 4, 77-80 Retrieved from

Guzman, M., Duarte, M.J., Blazquez, C., Ravina, J., Rosa, M.C., Galve-Roperh, I., Sanchez, C., Velasco, G., and Gonzalez-Feria, L. (2006). A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 95, 197-203 Retrieved from

GW-Pharma (2003). Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD. Drugs in R&D 4, 306-309 Retrieved from

Hagenbach, U., Luz, S., Ghafoor, N., Berger, J.M., Grotenhermen, F., Brenneisen, R., and Mader, M. (2007). The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 45, 551-562 Retrieved from

Hasenoehrl, C., Storr, M., and Schicho, R. (2017). Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? Expert Rev Gastroenterol Hepatol 11, 329-337 Retrieved from

Hazekamp, A., Bastola, K., Rashidi, H., Bender, J., and Verpoorte, R. (2007). Cannabis tea revisited: a systematic evaluation of the cannabinoid composition of cannabis tea. Journal of ethnopharmacology 113, 85-90 Retrieved from

Hess, E.J., Moody, K.A., Geffrey, A.L., Pollack, S.F., Skirvin, L.A., Bruno, P.L., Paolini, J.L., and Thiele, E.A. (2016). Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia 57, 1617-1624 Retrieved from

Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., and Izzo, A.A. (2004). Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. Journal of neurochemistry 89, 134-141 Retrieved from

Jatoi, A., Windschitl, H.E., Loprinzi, C.L., Sloan, J.A., Dakhil, S.R., Mailliard, J.A., Pundaleeka, S., Kardinal, C.G., Fitch, T.R., Krook, J.E., et al. (2002). Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20, 567-573 Retrieved from

Karst, M., and Bernateck, M. (2008). [Pain relief with cannabinoids-- the importance of endocannabinoids and cannabinoids for pain therapy]. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS 43, 522-528 Retrieved from

Kavia, R.B., De Ridder, D., Constantinescu, C.S., Stott, C.G., and Fowler, C.J. (2010). Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 16, 1349-1359 Retrieved from

Kim, K., Moore, D.H., Makriyannis, A., and Abood, M.E. (2006). AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. European journal of pharmacology 542, 100-105.

Koehler, J., Feneberg, W., Meier, M., and Pollmann, W. (2014). Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity. Int J Neurosci 124, 652-656 Retrieved from

Koppel, B.S., Brust, J.C., Fife, T., Bronstein, J., Youssof, S., Gronseth, G., and Gloss, D. (2014). Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82, 1556-1563 Retrieved from

Lahat, A., Lang, A., and Ben-Horin, S. (2012). Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion 85, 1-8 Retrieved from

Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., . . . Koethe (2012).  Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.  DTransl Psychiatry  2, e94, doi:10.1038/tp.2012.15

Leweke, F.M., Mueller, J.K., Lange, B., and Rohleder, C. (2016). Therapeutic Potential of Cannabinoids in Psychosis. Biol Psychiatry 79, 604-612 Retrieved from

Liang, C., McClean, M.D., Marsit, C., Christensen, B., Peters, E., Nelson, H.H., and Kelsey, K.T. (2009). A population-based case-control study of marijuana use and head and neck squamous cell carcinoma. Cancer Prev Res (Phila) 2, 759-768 Retrieved from

Lopez-Sendon Moreno, J.L., Garcia Caldentey, J., Trigo Cubillo, P., Ruiz Romero, C., Garcia Ribas, G., Alonso Arias, M.A., Garcia de Yebenes, M.J., Tolon, R.M., Galve-Roperh, I., Sagredo, O., et al. (2016). A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease. J Neurol 263, 1390-1400 Retrieved from

Lorente Fernandez, L., Monte Boquet, E., Perez-Miralles, F., Gil Gomez, I., Escutia Roig, M., Bosca Blasco, I., Poveda Andres, J.L., and Casanova-Estruch, B. (2014). Clinical experiences with cannabinoids in spasticity management in multiple sclerosis. Neurologia 29, 257-260 Retrieved from

Lotan, I., Treves, T.A., Roditi, Y., and Djaldetti, R. (2014). Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clinical neuropharmacology 37, 41-44 Retrieved from

Lynch, M.E., and Campbell, F. (2011). Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British journal of clinical pharmacology 72, 735-744 Retrieved from

Machado Rocha, F.C., Stefano, S.C., De Cassia Haiek, R., Rosa Oliveira, L.M., and Da Silveira, D.X. (2008). Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. European journal of cancer care 17, 431-443 Retrieved from

Maida, V., Ennis, M., Irani, S., Corbo, M., and Dolzhykov, M. (2008). Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. The journal of supportive oncology 6, 119-124 Retrieved from

Martin-Moreno, A.M., Reigada, D., Ramirez, B.G., Mechoulam, R., Innamorato, N., Cuadrado, A., and de Ceballos, M.L. (2011). Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol 79, 964-973 Retrieved from

Massot-Tarrus, A., and McLachlan, R.S. (2016). Marijuana use in adults admitted to a Canadian epilepsy monitoring unit. Epilepsy Behav 63, 73-78 Retrieved from

McGuire, P, Robson, P Cubala WJ et al., Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.  Am J Psychiatry (2018) 175 (3): 225-231

Mechoulam et al., (2014) Early phytocannabinoid chemistry to endocannabinoids  and beyond Nat Rev Neurosci.  Vol 14, Issue 11, pp 757-764

Merritt, J.C., Crawford, W.J., Alexander, P.C., Anduze, A.L., and Gelbart, S.S. (1980). Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 87, 222-228 Retrieved from

Morgan, C.J., Freeman, T.P., Schafer, G.L., and Curran, H.V. (2010). Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 35, 1879-1885 Retrieved from

Muller-Vahl, K.R., Prevedel, H., Theloe, K., Kolbe, H., Emrich, H.M., and Schneider, U. (2003). Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 28, 384-388 Retrieved from 

Muller-Vahl, K.R., Schneider, U., Koblenz, A., Jobges, M., Kolbe, H., Daldrup, T., and Emrich, H.M. (2002). Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35, 57-61 Retrieved from

Naftali, T., Bar-Lev Schleider, L., Dotan, I., Lansky, E.P., Sklerovsky Benjaminov, F., and Konikoff, F.M. (2013). Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol 11, 1276-1280 e1271 Retrieved from

Narang, S., Gibson, D., Wasan, A.D., Ross, E.L., Michna, E., Nedeljkovic, S.S., and Jamison, R.N. (2008). Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. The journal of pain : official journal of the American Pain Society 9, 254-264 Retrieved from

National Academies of Sciences, E., and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. (Washington DC: National Academies Press).

Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., et al. (2011). A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R)) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 18, 1122-1131 Retrieved from

Nurmikko, T.J., Serpell, M.G., Hoggart, B., Toomey, P.J., Morlion, B.J., and Haines, D. (2007). Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 133, 210-220 Retrieved from

Nguyen, B.M., Kim, D., Bricker, S., Bongard, F., Neville, A., Putnam, B., Smith, J., and Plurad, D. (2014). Effect of marijuana use on outcomes in traumatic brain injury. Am Surg 80, 979-983.

Pertwee, R.G. (1974). Tolerance to the effect of delta1-tetrahydrocannabinol on corticosterone levels in mouse plasma produced by repeated administration of cannabis extract or delta1-tetrahydrocannabinol. British journal of pharmacology 51, 391-397 Retrieved from

Plange, N., Arend, K.O., Kaup, M., Doehmen, B., Adams, H., Hendricks, S., Cordes, A., Huth, J., Sponsel, W.E., and Remky, A. (2007). Dronabinol and retinal hemodynamics in humans. Am J Ophthalmol 143, 173-174 Retrieved from

Portenoy, R.K., Ganae-Motan, E.D., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S., McQuade, R., Wright, S., and Fallon, M.T. (2012). Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. The journal of pain : official journal of the American Pain Society 13, 438-449 Retrieved from

Peball, M., et al., Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone. Ann Neurol, 2020.

Rabinak, C.A., Angstadt, M., Sripada, C.S., Abelson, J.L., Liberzon, I., Milad, M.R., and Phan, K.L. (2013). Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology 64, 396-402 Retrieved from

Raman, C., McAllister, S.D., Rizvi, G., Patel, S.G., Moore, D.H., and Abood, M.E. (2004). Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord 5, 33-39.

Ramirez, B.G., Blazquez, C., Gomez del Pulgar, T., Guzman, M., and de Ceballos, M.L. (2005). Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. The Journal of neuroscience : the official journal of the Society for Neuroscience 25, 1904-1913 Retrieved from

Regelson, W., Butler, J.R., Schulz, J., Kirk, T., Peek, L., Gree, M.L., and Zalis, M.O. (1976). Delta-9-THC as an effective antidepressant and appetitestimulating agent in advanced cancer patients. In Pharmacology of Marijuana. M.C. Braude, and S. Szara, eds. (New York, NY: Raven Press), pp. 763-776.

Rekand, T. (2014). THC:CBD spray and MS spasticity symptoms: data from latest studies. Eur Neurol 71 Suppl 1, 4-9 Retrieved from

Rhyne, D.N., Anderson, S.L., Gedde, M., and Borgelt, L.M. (2016). Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population. Pharmacotherapy 36, 505-510 Retrieved from

Rog, D.J., Nurmikko, T.J., Friede, T., and Young, C.A. (2005). Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65, 812-819 Retrieved from

Russo, E. (2004). History of cannabis as a medicine. In The Medicinal Uses of Cannabis and Cannabinoids. G.W. Guy, B.A. Whittle, and P.J. Robson, eds.

Russo, E.B. (2007). History of cannabis and its preparations in saga, science, and sobriquet. Chemistry & biodiversity 4, 1614-1648 Retrieved from 

Russo, M., Naro, A., Leo, A., Sessa, E., D'Aleo, G., Bramanti, P., and Calabro, R.S. (2016). Evaluating Sativex(R) in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis. Pain medicine 17, 1145-1154 Retrieved from

Sanchez-Ramos, J. (2013). Neon neurons. Neurology 80, 1815 Retrieved from

Sandyk, R., Snider, S.R., Consroe, P., and Elias, S.M. (1986). Cannabidiol in dystonic movement disorders. Psychiatry Res 18, 291 Retrieved from

Schwilke, E.W., Schwope, D.M., Karschner, E.L., Lowe, R.H., Darwin, W.D., Kelly, D.L., Goodwin, R.S., Gorelick, D.A., and Huestis, M.A. (2009). Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem 55, 2180-2189 Retrieved from

Schurman, L.D., and Lichtman, A.H. (2017). Endocannabinoids: A Promising Impact for Traumatic Brain Injury. Frontiers in pharmacology 8, 69.

Serpell, M., Ratcliffe, S., Hovorka, J., Schofield, M., Taylor, L., Lauder, H., and Ehler, E. (2014). A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European journal of pain 18, 999-1012 Retrieved from

Shelef, A., Barak, Y., Berger, U., Paleacu, D., Tadger, S., Plopsky, I., and Baruch, Y. (2016). Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study. Journal of Alzheimer's disease : JAD 51, 15-19 Retrieved from

Shohet, A., Khlebtovsky, A., Roizen, N., Roditi, Y., and Djaldetti, R. (2017). Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson's disease. European journal of pain 21, 486-493 Retrieved from

Sieradzan, K.A., Fox, S.H., Hill, M., Dick, J.P., Crossman, A.R., and Brotchie, J.M. (2001). Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57, 2108-2111 Retrieved from 

Skrabek, R.Q., Galimova, L., Ethans, K., and Perry, D. (2008). Nabilone for the treatment of pain in fibromyalgia. The journal of pain : official journal of the American Pain Society 9, 164-173 Retrieved from

Snider, S., and Consroe, P. (1984). Treatment of Meige's syndrome with cannabidiol. Neurology 34, 147


Sutton, I.R., and Daeninck, P. (2006). Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain. The journal of supportive oncology 4, 531-535 Retrieved from

Tashkin, D.P., Shapiro, B.J., and Frank, I.M. (1974). Acute effects of smoked marijuana and oral delta9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. Am Rev Respir Dis 109, 420-428 Retrieved from

Tomida, I., Azuara-Blanco, A., House, H., Flint, M., Pertwee, R.G., and Robson, P.J. (2006). Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma 15, 349-353 Retrieved from

Torres, S., Lorente, M., Rodriguez-Fornes, F., Hernandez-Tiedra, S., Salazar, M., Garcia-Taboada, E., Barcia, J., Guzman, M., and Velasco, G. (2011). A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 10, 90-103.

Turcotte, D., Doupe, M., Torabi, M., Gomori, A., Ethans, K., Esfahani, F., Galloway, K., and Namaka, M. (2015). Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. Pain medicine 16, 149-159 Retrieved from

Tzadok, M., Uliel-Siboni, S., Linder, I., Kramer, U., Epstein, O., Menascu, S., Nissenkorn, A., Yosef, O.B., Hyman, E., Granot, D., et al. (2016). CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Seizure 35, 41-44 Retrieved from

Uribe Roca, M.C., Micheli, F., and Viotti, R. (2005). Cannabis sativa and dystonia secondary to Wilson's disease. Mov Disord 20, 113-115 Retrieved from 

Valdeolivas, S., Sagredo, O., Delgado, M., Pozo, M.A., and Fernandez-Ruiz, J. (2017). Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease. International journal of molecular sciences 18 Retrieved from

Velasco, G., Sanchez, C., and Guzman, M. (2016). Anticancer mechanisms of cannabinoids. Curr Oncol 23, S23-32 Retrieved from

Wachtel, S.R., ElSohly, M.A., Ross, S.A., Ambre, J., and de Wit, H. (2002). Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology 161, 331-339 Retrieved from

Wade, D.T., Makela, P., Robson, P., House, H., and Bateman, C. (2004). Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10, 434-441 Retrieved from

Wade, D.T., Robson, P., House, H., Makela, P., and Aram, J. (2003). A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical rehabilitation 17, 21-29 Retrieved from

Waissengrin, B., Urban, D., Leshem, Y., Garty, M., and Wolf, I. (2015). Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience. J Pain Symptom Manage 49, 223-230 Retrieved from

Wallace, M.S., Marcotte, T.D., Umlauf, A., Gouaux, B., and Atkinson, J.H. (2015). Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. The journal of pain : official journal of the American Pain Society 16, 616-627 Retrieved from

Walther, S., Mahlberg, R., Eichmann, U., and Kunz, D. (2006). Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology 185, 524-528 Retrieved from

Ware, M.A., Adams, H., and Guy, G.W. (2005). The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract 59, 291-295 Retrieved from

Ware, M.A., Fitzcharles, M.A., Joseph, L., and Shir, Y. (2010a). The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia and analgesia 110, 604-610 Retrieved from

Ware, M.A., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T., Gamsa, A., Bennett, G.J., and Collet, J.P. (2010b). Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 182, E694-701 Retrieved from

Whiting, P.F., Wolff, R.F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A.V., Keurentjes, J.C., Lang, S., Misso, K., Ryder, S., et al. (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA 313, 2456-2473 Retrieved from

Wilsey, B., Marcotte, T., Deutsch, R., Gouaux, B., Sakai, S., and Donaghe, H. (2013). Low-dose vaporized cannabis significantly improves neuropathic pain. The journal of pain : official journal of the American Pain Society 14, 136-148 Retrieved from

Woodward, M.R., Harper, D.G., Stolyar, A., Forester, B.P., and Ellison, J.M. (2014). Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. Am J Geriatr Psychiatry 22, 415-419 Retrieved from

Zajicek, J.P., Hobart, J.C., Slade, A., Barnes, D., Mattison, P.G., and Group, M.R. (2012). Multiple sclerosis and extract of cannabis: results of the MUSEC trial. Journal of neurology, neurosurgery, and psychiatry 83, 1125-1132 Retrieved from

Zuardi, A.W., Crippa, J.A., Hallak, J.E., Pinto, J.P., Chagas, M.H., Rodrigues, G.G., Dursun, S.M., and Tumas, V. (2009). Cannabidiol for the treatment of psychosis in Parkinson's disease. Journal of psychopharmacology 23, 979-983 Retrieved from, P, Robson, P Cubala WJ et al., Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.  Am J Psychiatry (2018) 175 (3): 225-231

bottom of page